Tele: 561.316.3330

Breaking Medical Device Industry News

Friday, October 22, 2021


HomeACQUISITIONS and MERGERSArlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through...

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of EastCoast Bio. Arlington Scientific will now be the exclusive worldwide manufacturer of these proprietary blocking buffers for markets including In-Vitro Diagnostic (IVD) manufacturers and for research and development institutions.

“This acquisition will provide strategic value to Arlington Scientific in the form of new product markets, expansion of its manufacturing capabilities, increased sales and new customers. This is in line with ASI’s strategy of being a progressive industry leader through the pursuit of quality products, superior customer service, high corporate values, and a genuine appreciation for each customer,” said David Porter, Chief Business Development officer for Arlington Scientific.

ASI is an FDA registered establishment with over 36 years of medical device manufacturing expertise in diagnostic reagents and serological test kits. ASI is at the forefront of innovation and was the first to develop an automated nontreponemal algorithm for the detection of syphilis; the first to develop the only automated nontreponemal (RPR) syphilis analyzer FDA cleared for diagnostic, blood donor screening and cadaveric (non-heartbeating) donor screening; the first to include mercury free RPR reagents, implementation of liquid controls, screw cap lids, warp resistant test cards, extended shelf life for reagents and developing in-vitro diagnostic RPR tests for use with CPD and CPDA-1 anticoagulants.

Product Overview:

Balance Blocking Buffer (ELISA/WB/Lateral Flow)Universal blocking reagent provides superior blocking in sensitive assay systems (Available in three formulations, with PBS, PBS with a surfactant or with Tris).
Aquatic Block Serum FreeFormerly called SeaBlock Serum Free (Lateral Flow/ELISA)Serum and plasma-free optimized for use with nitrocellulose in lateral flow assays and ELISA systems (Available in two formulations, with PBS or Tris).
Aquatic BlockFormerly called SeaBlock(ELISA/EIA/WB)Formulated for ELISA assay development. Can be diluted to 1:1 to 1:50 to reduce signal-to-noise ratio (Available in two formulations, with PBS or Tris).
AquaBlock (WB/EIA/Chemiluminescence)Significantly reduces non-specific protein attachment when used with a blotting membrane.


United States Insulin Delivery Devices Market Report 2021

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends.

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy